Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland. more
Time Frame | GANX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.42% | -0.94% | -2.6% |
1-Month Return | -13.74% | -5.08% | -1.08% |
3-Month Return | 1.29% | -10.62% | 3.45% |
6-Month Return | 21.71% | -6.18% | 8.57% |
1-Year Return | -41.42% | 1.98% | 24.3% |
3-Year Return | -72.43% | -0.93% | 25.58% |
5-Year Return | -85.98% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 41.30K | 28.88K | 164.99K | 140.11K | 55.18K | [{"date":"2019-12-31","value":25.03,"profit":true},{"date":"2020-12-31","value":17.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.92,"profit":true},{"date":"2023-12-31","value":33.44,"profit":true}] |
Cost of Revenue | - | 2.26M | 7.16M | 64.17K | 80.38K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":31.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.9,"profit":true},{"date":"2023-12-31","value":1.12,"profit":true}] |
Gross Profit | 41.30K | (2.23M) | (7.00M) | 75.94K | (25.20K) | [{"date":"2019-12-31","value":54.39,"profit":true},{"date":"2020-12-31","value":-2936.95,"profit":false},{"date":"2021-12-31","value":-9216.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-33.19,"profit":false}] |
Gross Margin | 100.00% | (7722.46%) | (4242.11%) | 54.20% | (45.67%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7722.46,"profit":false},{"date":"2021-12-31","value":-4242.11,"profit":false},{"date":"2022-12-31","value":54.2,"profit":true},{"date":"2023-12-31","value":-45.67,"profit":false}] |
Operating Expenses | 2.14M | 3.51M | 13.99M | 17.92M | 22.31M | [{"date":"2019-12-31","value":9.6,"profit":true},{"date":"2020-12-31","value":15.73,"profit":true},{"date":"2021-12-31","value":62.72,"profit":true},{"date":"2022-12-31","value":80.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (2.10M) | (3.48M) | (13.83M) | (17.78M) | (22.25M) | [{"date":"2019-12-31","value":-210010900,"profit":false},{"date":"2020-12-31","value":-347944900,"profit":false},{"date":"2021-12-31","value":-1382617300,"profit":false},{"date":"2022-12-31","value":-1777704500,"profit":false},{"date":"2023-12-31","value":-2225313300,"profit":false}] |
Total Non-Operating Income/Expense | (106.76K) | (89.21K) | (47.93K) | 654.64K | 616.63K | [{"date":"2019-12-31","value":-16.31,"profit":false},{"date":"2020-12-31","value":-13.63,"profit":false},{"date":"2021-12-31","value":-7.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.19,"profit":true}] |
Pre-Tax Income | (2.19M) | (3.57M) | (13.89M) | (17.50M) | (22.19M) | [{"date":"2019-12-31","value":-218633100,"profit":false},{"date":"2020-12-31","value":-357229600,"profit":false},{"date":"2021-12-31","value":-1388659800,"profit":false},{"date":"2022-12-31","value":-1749776200,"profit":false},{"date":"2023-12-31","value":-2218824500,"profit":false}] |
Income Taxes | 7.11K | 5.39K | 4.01K | 92.98K | 79.28K | [{"date":"2019-12-31","value":7.65,"profit":true},{"date":"2020-12-31","value":5.79,"profit":true},{"date":"2021-12-31","value":4.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.26,"profit":true}] |
Income After Taxes | (2.19M) | (3.58M) | (13.89M) | (17.59M) | (22.27M) | [{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2226752000,"profit":false}] |
Income From Continuous Operations | (2.19M) | (3.58M) | (13.89M) | (17.59M) | (22.22M) | [{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2221801700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.19M) | (3.58M) | (13.89M) | (17.59M) | (22.27M) | [{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2226752000,"profit":false}] |
EPS (Diluted) | - | (0.73) | (1.51) | (1.48) | (1.78) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-72.59,"profit":false},{"date":"2021-12-31","value":-151,"profit":false},{"date":"2022-12-31","value":-148,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GANX | |
---|---|
Cash Ratio | 2.62 |
Current Ratio | 2.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GANX | |
---|---|
ROA (LTM) | -72.96% |
ROE (LTM) | -188.83% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GANX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.38 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.62 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GANX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 925.92 |
P/B | 4.67 |
Price/FCF | NM |
EV/R | 138.33 |
EV/Ebitda | NM |
Gain Therapeutics Inc (GANX) share price today is $1.57
Yes, Indians can buy shares of Gain Therapeutics Inc (GANX) on Vested. To buy Gain Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GANX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Gain Therapeutics Inc (GANX) via the Vested app. You can start investing in Gain Therapeutics Inc (GANX) with a minimum investment of $1.
You can invest in shares of Gain Therapeutics Inc (GANX) via Vested in three simple steps:
The 52-week high price of Gain Therapeutics Inc (GANX) is $5.33. The 52-week low price of Gain Therapeutics Inc (GANX) is $0.89.
The price-to-earnings (P/E) ratio of Gain Therapeutics Inc (GANX) is
The price-to-book (P/B) ratio of Gain Therapeutics Inc (GANX) is 4.67
The dividend yield of Gain Therapeutics Inc (GANX) is 0.00%
The market capitalization of Gain Therapeutics Inc (GANX) is $41.38M
The stock symbol (or ticker) of Gain Therapeutics Inc is GANX